Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer
- PMID: 21057535
- DOI: 10.1038/onc.2010.509
Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer
Abstract
Epithelial-to-mesenchymal transition (EMT) is a critical event in the progression toward cancer metastasis. The intermediate filament protein vimentin is an important marker of EMT and a requisite regulator of mesenchymal cell migration. However, it is not known how vimentin functionally contributes to cancer cell invasion. Here, we report that ectopic expression of oncogenic H-Ras-V12G and Slug induces vimentin expression and migration in pre-malignant breast epithelial cells. Conversely, vimentin expression is necessary for Slug- or H-Ras-V12G-induced EMT-associated migration. Furthermore, silencing of vimentin in breast epithelial cells results in specific changes in invasiveness-related gene expression including upregulation of RAB25 (small GTPase Rab25) and downregulation of AXL (receptor tyrosine kinase Axl), PLAU (plasminogen activator, urokinase) and ITGB4 (integrin β4-subunit). Importantly, gene expression profiling analyses reveal that vimentin expression correlates positively/negatively with these genes also in multiple breast cancer cell lines and breast cancer patient samples. Focusing on the tyrosine kinase Axl, we show that induction of vimentin by EMT is associated with upregulation of Axl expression and that Axl enhances the migratory activity of pre-malignant breast epithelial cells. Using null and knock-down cells and overexpression models, we also show that regulation of breast cancer cell migration in two- and three-dimensional matrices by vimentin is Axl- dependent and that Axl functionally contributes to lung extravasation of breast cancer cells in mice. In conclusion, our data show that vimentin functionally contributes to EMT and is required for induction of Axl expression. Moreover, these results provide a molecular explanation for vimentin-dependent cancer cell migration during EMT by identifying Axl as a key proximal component in this process.
Similar articles
-
Notch1 signaling regulates the epithelial-mesenchymal transition and invasion of breast cancer in a Slug-dependent manner.Mol Cancer. 2015 Feb 3;14(1):28. doi: 10.1186/s12943-015-0295-3. Mol Cancer. 2015. PMID: 25645291 Free PMC article.
-
Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis.Clin Cancer Res. 2017 Jun 1;23(11):2806-2816. doi: 10.1158/1078-0432.CCR-16-1316. Epub 2016 Dec 6. Clin Cancer Res. 2017. PMID: 27923843
-
ΔNp63α Promotes Breast Cancer Cell Motility through the Selective Activation of Components of the Epithelial-to-Mesenchymal Transition Program.Cancer Res. 2015 Sep 15;75(18):3925-35. doi: 10.1158/0008-5472.CAN-14-3363. Epub 2015 Aug 19. Cancer Res. 2015. PMID: 26292362 Free PMC article.
-
Epithelial-to-mesenchymal transition: lessons from development, insights into cancer and the potential of EMT-subtype based therapeutic intervention.Phys Biol. 2019 May 7;16(4):041004. doi: 10.1088/1478-3975/ab157a. Phys Biol. 2019. PMID: 30939460 Review.
-
AXL-Driven EMT State as a Targetable Conduit in Cancer.Cancer Res. 2017 Jul 15;77(14):3725-3732. doi: 10.1158/0008-5472.CAN-17-0392. Epub 2017 Jun 30. Cancer Res. 2017. PMID: 28667075 Review.
Cited by
-
Variable metastatic potentials correlate with differential plectin and vimentin expression in syngeneic androgen independent prostate cancer cells.PLoS One. 2013 May 22;8(5):e65005. doi: 10.1371/journal.pone.0065005. Print 2013. PLoS One. 2013. PMID: 23717685 Free PMC article.
-
Risk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon?EPMA J. 2013 Feb 19;4(1):6. doi: 10.1186/1878-5085-4-6. EPMA J. 2013. PMID: 23418957 Free PMC article.
-
NOTCH3 limits the epithelial-mesenchymal transition and predicts a favorable clinical outcome in esophageal cancer.Cancer Med. 2021 Jun;10(12):3986-3996. doi: 10.1002/cam4.3933. Epub 2021 May 27. Cancer Med. 2021. PMID: 34042293 Free PMC article.
-
MDGA2 is a novel tumour suppressor cooperating with DMAP1 in gastric cancer and is associated with disease outcome.Gut. 2016 Oct;65(10):1619-31. doi: 10.1136/gutjnl-2015-309276. Epub 2015 Jul 23. Gut. 2016. PMID: 26206665 Free PMC article.
-
A synergic approach to enhance long-term culture and manipulation of MiaPaCa-2 pancreatic cancer spheroids.Sci Rep. 2020 Jun 23;10(1):10192. doi: 10.1038/s41598-020-66908-8. Sci Rep. 2020. PMID: 32576846 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous